Skip to main content
Erschienen in:

02.07.2022 | Epidemiology

Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol consumption recommendations

verfasst von: Ashley M. Geczik, Jennifer S. Ferris, Mary Beth Terry, Irene L. Andrulis, Saundra S. Buys, Mary B. Daly, John L. Hopper, Esther M. John, Allison W. Kurian, Melissa C. Southey, Yuyan Liao, Jeanine M. Genkinger

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The American Cancer Society (ACS) published an updated Guideline for Cancer Prevention (ACS Guideline) in 2020. Research suggests that adherence to the 2012 ACS Guideline might lower breast cancer risk, but there is limited evidence that this applies to women at increased familial and genetic risk of breast cancer.

Methods

Using the Breast Cancer Family Registry (BCFR), a cohort enriched for increased familial and genetic risk of breast cancer, we examined adherence to three 2020 ACS Guideline recommendations (weight management (body mass index), physical activity, and alcohol consumption) with breast cancer risk in 9615 women. We used Cox proportional hazard regression modeling to calculate hazard ratios (HRs) and 95% confidence intervals (CI) overall and stratified by BRCA1 and BRCA2 pathogenic variant status, family history of breast cancer, menopausal status, and estrogen receptor-positive (ER +) breast cancer.

Results

We observed 618 incident invasive or in situ breast cancers over a median 12.9 years. Compared with being adherent to none (n = 55 cancers), being adherent to any ACS recommendation (n = 563 cancers) was associated with a 27% lower breast cancer risk (HR = 0.73, 95% CI: 0.55–0.97). This was evident for women with a first-degree family history of breast cancer (HR = 0.68, 95% CI: 0.50–0.93), women without BRCA1 or BRCA2 pathogenic variants (HR = 0.71, 95% CI: 0.53–0.95), postmenopausal women (HR = 0.63, 95% CI: 0.44–0.89), and for risk of ER+ breast cancer (HR = 0.63, 95% CI: 0.40–0.98).

Discussion

Adherence to the 2020 ACS Guideline recommendations for BMI, physical activity, and alcohol consumption could reduce breast cancer risk for postmenopausal women and women at increased familial risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL et al (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33CrossRef Siegel RL et al (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33CrossRef
2.
Zurück zum Zitat Johnson RH, Chien FL, Bleyer A (2013) Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 309(8):800–805CrossRef Johnson RH, Chien FL, Bleyer A (2013) Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 309(8):800–805CrossRef
4.
Zurück zum Zitat Claus EB et al (1998) Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst 90(23):1824–1829CrossRef Claus EB et al (1998) Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst 90(23):1824–1829CrossRef
5.
Zurück zum Zitat Dombernowsky SL et al (2009) Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 18(8):2339–2342CrossRef Dombernowsky SL et al (2009) Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 18(8):2339–2342CrossRef
6.
Zurück zum Zitat Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416CrossRef Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416CrossRef
7.
Zurück zum Zitat Narod SA et al (2006) Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 7(5):402–406CrossRef Narod SA et al (2006) Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 7(5):402–406CrossRef
8.
Zurück zum Zitat Association BC, C. et al (2021) Breast cancer risk genes—association analysis in more than 113,000 women. N Engl J Med 384(5):428–439CrossRef Association BC, C. et al (2021) Breast cancer risk genes—association analysis in more than 113,000 women. N Engl J Med 384(5):428–439CrossRef
9.
Zurück zum Zitat Kushi LH et al (2012) American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 62(1):30–67CrossRef Kushi LH et al (2012) American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 62(1):30–67CrossRef
11.
Zurück zum Zitat Kabat GC et al (2015) Adherence to cancer prevention guidelines and cancer incidence, cancer mortality, and total mortality: a prospective cohort study. Am J Clin Nutr 101(3):558–569CrossRef Kabat GC et al (2015) Adherence to cancer prevention guidelines and cancer incidence, cancer mortality, and total mortality: a prospective cohort study. Am J Clin Nutr 101(3):558–569CrossRef
12.
Zurück zum Zitat Thomson CA et al (2014) Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women’s health initiative. Cancer Prev Res (Phila) 7(1):42–53CrossRef Thomson CA et al (2014) Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women’s health initiative. Cancer Prev Res (Phila) 7(1):42–53CrossRef
13.
Zurück zum Zitat Catsburg C, Miller AB, Rohan TE (2014) Adherence to cancer prevention guidelines and risk of breast cancer. Int J Cancer 135(10):2444–2452CrossRef Catsburg C, Miller AB, Rohan TE (2014) Adherence to cancer prevention guidelines and risk of breast cancer. Int J Cancer 135(10):2444–2452CrossRef
14.
Zurück zum Zitat Terry MB et al (2016) Cohort profile: the breast cancer prospective family study cohort (ProF-SC). Int J Epidemiol 45(3):683–692CrossRef Terry MB et al (2016) Cohort profile: the breast cancer prospective family study cohort (ProF-SC). Int J Epidemiol 45(3):683–692CrossRef
15.
Zurück zum Zitat John EM et al (2004) The breast cancer family registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6(4):R375–R389CrossRef John EM et al (2004) The breast cancer family registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6(4):R375–R389CrossRef
16.
Zurück zum Zitat von Elm E et al (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349CrossRef von Elm E et al (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349CrossRef
17.
Zurück zum Zitat Kehm RD et al (2020) Recreational physical activity is associated with reduced breast cancer risk in adult women at high risk for breast cancer: A cohort study of women selected for familial and genetic risk. Cancer Res 80(1):116–125CrossRef Kehm RD et al (2020) Recreational physical activity is associated with reduced breast cancer risk in adult women at high risk for breast cancer: A cohort study of women selected for familial and genetic risk. Cancer Res 80(1):116–125CrossRef
18.
Zurück zum Zitat Kehm RD et al (2019) Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Res 21(1):52CrossRef Kehm RD et al (2019) Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Res 21(1):52CrossRef
19.
Zurück zum Zitat Zeinomar N et al (2019) Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the prospective family study cohort (ProF-SC). Breast Cancer Res 21(1):128CrossRef Zeinomar N et al (2019) Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the prospective family study cohort (ProF-SC). Breast Cancer Res 21(1):128CrossRef
20.
Zurück zum Zitat Zeinomar N et al (2019) Benign breast disease increases breast cancer risk independent of underlying familial risk profile: findings from a prospective family study cohort. Int J Cancer 145(2):370–379CrossRef Zeinomar N et al (2019) Benign breast disease increases breast cancer risk independent of underlying familial risk profile: findings from a prospective family study cohort. Int J Cancer 145(2):370–379CrossRef
21.
Zurück zum Zitat Neuhausen SL et al (2009) BRCA1 and BRCA2 mutation carriers in the breast cancer family registry: an open resource for collaborative research. Breast Cancer Res Treat 116(2):379–386CrossRef Neuhausen SL et al (2009) BRCA1 and BRCA2 mutation carriers in the breast cancer family registry: an open resource for collaborative research. Breast Cancer Res Treat 116(2):379–386CrossRef
22.
Zurück zum Zitat Terry MB et al (2019) 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol 20(4):504–517CrossRef Terry MB et al (2019) 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol 20(4):504–517CrossRef
23.
Zurück zum Zitat Cloud AJ et al (2015) The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry. Breast Cancer Res Treat 149(2):537–546CrossRef Cloud AJ et al (2015) The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry. Breast Cancer Res Treat 149(2):537–546CrossRef
24.
Zurück zum Zitat McCullough ML et al (2011) Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease, and all-cause mortality. Cancer Epidemiol Biomarkers Prev 20(6):1089–1097CrossRef McCullough ML et al (2011) Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease, and all-cause mortality. Cancer Epidemiol Biomarkers Prev 20(6):1089–1097CrossRef
25.
Zurück zum Zitat Warren Andersen S et al (2016) Adherence to cancer prevention guidelines and cancer risk in low-income and African American populations. Cancer Epidemiol Biomarkers Prev 25(5):846–853CrossRef Warren Andersen S et al (2016) Adherence to cancer prevention guidelines and cancer risk in low-income and African American populations. Cancer Epidemiol Biomarkers Prev 25(5):846–853CrossRef
26.
Zurück zum Zitat Spector D, Deroo LA, Sandler DP (2011) Lifestyle behaviors in black and white women with a family history of breast cancer. Prev Med 52(5):394–397CrossRef Spector D, Deroo LA, Sandler DP (2011) Lifestyle behaviors in black and white women with a family history of breast cancer. Prev Med 52(5):394–397CrossRef
27.
Zurück zum Zitat Gail MH et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886CrossRef Gail MH et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886CrossRef
28.
Zurück zum Zitat Rothman KJ (1986) Interactions between causes. In: Modern epidemiology. Little, Brown & Co, Boston, pp 311–326 Rothman KJ (1986) Interactions between causes. In: Modern epidemiology. Little, Brown & Co, Boston, pp 311–326
29.
Zurück zum Zitat Shantakumar S et al (2007) Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 165(10):1187–1198CrossRef Shantakumar S et al (2007) Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 165(10):1187–1198CrossRef
30.
Zurück zum Zitat Buchanan AH et al (2017) Adherence to recommended risk management among unaffected women with a BRCA mutation. J Genet Couns 26(1):79–92CrossRef Buchanan AH et al (2017) Adherence to recommended risk management among unaffected women with a BRCA mutation. J Genet Couns 26(1):79–92CrossRef
31.
Zurück zum Zitat Cifu G, Arem H (2018) Adherence to lifestyle-related cancer prevention guidelines and breast cancer incidence and mortality. Ann Epidemiol 28(11):767-773.e1CrossRef Cifu G, Arem H (2018) Adherence to lifestyle-related cancer prevention guidelines and breast cancer incidence and mortality. Ann Epidemiol 28(11):767-773.e1CrossRef
Metadaten
Titel
Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol consumption recommendations
verfasst von
Ashley M. Geczik
Jennifer S. Ferris
Mary Beth Terry
Irene L. Andrulis
Saundra S. Buys
Mary B. Daly
John L. Hopper
Esther M. John
Allison W. Kurian
Melissa C. Southey
Yuyan Liao
Jeanine M. Genkinger
Publikationsdatum
02.07.2022
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2022
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-022-06656-7

Neu im Fachgebiet Onkologie

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Brustkrebstherapie: zu wenig Aufklärung über Nebenwirkungen?

Ergebnisse eines internationalen Surveys legen nahe, dass die Aufklärung über Nebenwirkungen einer Brustkrebstherapie häufig unzureichend ausfällt bzw. zu spät erfolgt.

Neue chemotherapiefreie Kombinationstherapie punktet bei CLL

Zwischenergebnisse der Phase-III-Studie AMPLIFY sprechen dafür, dass die zeitlich begrenzte Behandlung mit Acalabrutinib und Venetoclax fitte Personen mit chronischer lymphatischer Leukämie länger leben lässt als eine Chemoimmuntherapie.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.